Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China... Show more
Baird Medical Investment Holdings Ltd. is a Guangzhou, China-based medical device company founded in 2012. The company designs, develops, manufactures, and sells minimally invasive microwave ablation (MWA) systems and needles used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and uterine fibroids. Its lead product is a microwave ablation system that received U.S. FDA 510(k) clearance for soft tissue ablation and is being launched in the United States primarily for the treatment of benign thyroid nodules. Baird Medical was the first company to obtain a Class III medical device registration in China for MWA devices specifically indicated for thyroid nodules, and it is also developing IRE-based products and an AI-powered robotic ablation system. The company listed on Nasdaq in October 2024 through a business combination with ExcelFin Acquisition Corp., and investors follow the stock for its U.S. commercialization progress and expanding pipeline.
Over the last 30 days, BDMD declined from a close of about $0.75 to roughly $0.14, a drop of approximately 81.6%. The decline was not linear: the stock traded near $0.75 in early October before sharp, high-volume selloffs in late October accelerated the move toward $0.14.
The quarterly picture is similarly negative. From about $1.22 in early August, shares fell to roughly $0.14 by early November, a decline of nearly 89%. This reflects a sustained downward trend rather than a single isolated event, with selling pressure intensifying after a registered offering and a ratings downgrade.
Several verified factors contributed to the sharp decline. On September 24, 2026, the company priced an offering under its shelf registration, raising dilution concerns in an already thinly traded security. The company had earlier filed a $50 million shelf registration statement on August 6, 2026. On October 6, 2026, Weiss Ratings issued a downgrade on Baird Medical with a "Sell" rating, adding to negative sentiment.
The selloff pushed the stock below $1.00, a threshold that raises Nasdaq minimum bid price listing compliance considerations. Trading volume expanded dramatically in late October and early November, reflecting heavy selling pressure in a low-priced, low-float micro-cap. Broader weakness among Chinese concept stocks during October also weighed on the shares, compounding company-specific concerns around liquidity and the pace at which regulatory approvals are converting into commercial sales.
The multi-month downtrend reflects a broader narrative around a China-based micro-cap navigating a transition toward U.S. commercialization. In August 2026, the company's shelf registration and prospectus updates highlighted a resale overhang and ongoing China-related and Holding Foreign Companies Accountable Act (HFCAA) risks. In September, preliminary H1 2026 results showed revenue up 24.6% year over year and a swing to a narrow net profit, but the figures were preliminary and unaudited, and full-year 2025 revenue had fallen 39.2% due to a policy-related slowdown in mainland China. The combination of modest profitability, a low cash balance, dilution risk, and a sub-$1.00 share price kept sentiment under pressure throughout the quarter.
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading bots drawn from hundreds of AI-driven strategies that monitor thousands of tickers. Rather than listing every available bot, the section highlights top-performing and currently relevant robots so traders can quickly identify strategies gaining traction in real time. Each bot differs in its trading approach, timeframe, and performance metrics, which allows users to compare candidates based on their own objectives and risk tolerance. For those interested in complementing manual research with data-driven signals, browsing the Trending AI Robots section can offer a useful starting point for discovering how automated strategies are positioning in current market conditions.
Going forward, investors are likely to focus on whether Baird Medical's FDA-cleared microwave ablation system converts into sustained U.S. sales, and whether international regulatory approvals in markets such as Vietnam and Egypt translate into reported revenue. Audited interim financial results, any further capital-raising activity under the shelf registration, and the company's cash position will also be closely monitored. Listing compliance remains a key watch item while shares trade below $1.00, as does any update on auditor-related HFCAA risks. Developments in mainland China healthcare policy, which contributed to the 2025 revenue decline, and the broader sentiment toward Chinese concept stocks may continue to influence price action. These are informational considerations only and not investment recommendations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 31 cases where BDMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BDMD's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on BDMD as a result. In 32 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.
The Moving Average Convergence Divergence (MACD) for BDMD just turned positive on November 11, 2026. Looking at past instances where BDMD's MACD turned positive, the stock continued to rise in 20 of 46 cases over the following month. The odds of a continued upward trend are 43%.
Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 70 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BDMD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.081) is normal, around the industry mean (4.142). P/E Ratio (-0.159) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices